Marine non-glycosaminoglycan sulfated glycans as potential pharmaceuticals

Pharmaceuticals

Volumn 8, Issue 4, 2015, Pages 848-864

  Pomin, Vitor H ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Angiogenesis; Cancer; Coagulation; Inflammation; Marine glycans; Microbial infection; Sulfated fucans; Sulfated galactans; Thrombosis

Indexed keywords

CHONDROITIN SULFATE; FIBROBLAST GROWTH FACTOR 2; FUCAN DERIVATIVE; GALACTAN DERIVATIVE; GLYCOSAMINOGLYCAN POLYSULFATE; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMINO ACID SUBSTITUTION; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; CELL INTERACTION; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SULFATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84949795414     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph8040848     Document Type: Review

References (91)

1. Volpi, N. Therapeutic applications of glycosaminoglycans. Curr. Med. Chem. 2006, 13, 1799–1810.
2. Pomin, V.H. A dilemma in the glycosaminoglycan-based therapy: Synthetic or naturally unique molecules? Med. Res. Rev. 2015, 35, 1195–1219.
3. Gray, E.; Hogwood, J.; Mulloy, B. The anticoagulant and antithrombotic mechanisms of heparin. Handb. Exp. Pharmacol. 2012, 207, 43–61.
4. Hirsh, J.; Anand, S.S.; Halperin, J.L.; Fuster, V. Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation 2001, 103, 2994–3018.
5. Uebelhart, D. Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage 2008, 16, S19–S21.
6. Conrozier, T. Anti-arthrosis treatments: Efficacy and tolerance of chondroitin sulfates (CS 4&6). Presse Med. 1998, 27, 1862–1865.
7. Pomin, V.H.; Piquet, A.A.; Pereira, M.S.; Mourão, P.A. Residual keratan sulfate in chondroitin sulfate formulations for oral administration. Carbohydr. Polym. 2012, 90, 839–846.
8. Pomin, V.H. Keratan sulfate: An up-to-date review. Int. J. Biol. Macromol. 2015, 72, 282–289.
9. Maruyama, H.; Morikawa, K.; Tawada, A.; Miyauchi, S.; Yoshida, K.; Asari, A. Keratan Sulfate Oligosaccharide Fraction and Pharmaceutical Containing the Same. U.S. Patent 6,159,954 A., 12 December 2000.
10. Crowther, M.A.; Warkentin, T.E. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008, 111, 4871–4879.
11. Babikian, V.L.; Kase, C.S.; Pessin, M.S.; Norrving, B.; Gorelick, P.B. Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke 1989, 20, 1500–1503.
12. Kelton, J.G.; Hirsh, J. Bleeding associated with antithrombotic therapy. Semin. Hematol. 1980, 17, 259–379.
13. Funderburgh, J.L. Keratan sulfate: Structure, biosynthesis, and function. Glycobiology 2000, 10, 951–958.
14. Pomin, V.H. Mourão, P.A. Structure, biology, evolution, and medical importance of sulfated fucans and galactans. Glycobiology 2008, 18, 1016–1027.
15. Pomin, V.H. Fucanomics and galactanomics: marine distribution, medicinal impact, conceptions, and challenges. Mar. Drugs 2012, 10, 793–811.
16. Pomin, V.H. Fucanomics and galactanomics: Current status in drug discovery, mechanisms of action and role of the well-defined structures. Biochim. Biophys. Acta 2012, 1820, 1971–1979.
17. Glauser, B.F.; Rezende, R.M.; Melo, F.R.; Pereira, M.S.; Francischetti, I.M.; Monteiro, R.Q.; Rezaie, A.R.; Mourão, P.A. Anticoagulant activity of a sulfated galactan: Serpin-independent effect and specific interaction with factor Xa. Thromb. Haemost. 2009, 102, 1183–1193.
18. Glauser, B.F.; Mourão, P.A.; Pomin, V.H. Marine sulfated glycans with serpin-unrelated anticoagulant properties. Adv. Clin. Chem. 2013, 62, 269–303.
19. Quinderé, A.L.; Santos, G.R.; Oliveira, S.N.; Glauser, B.F.; Fontes, B.P.; Queiroz, I.N.; Benevides, N.M.; Pomin, V.H.; Mourão, P.A. Is the antithrombotic effect of sulfated galactans independent of serpin? J. Thromb. Haemost. 2014, 12, 43–53.
20. Pomin, V.H.; Pereira, M.S.; Valente, A.P.; Tollefsen, D.M.; Pavão, M.S.; Mourão, P.A. Selective cleavage and anticoagulant activity of a sulfated fucan: stereospecific removal of a 2-sulfate ester from the polysaccharide by mild acid hydrolysis, preparation of oligosaccharides, and heparin cofactor II-dependent anticoagulant activity. Glycobiology 2005, 15, 369–381.
21. Mourão, P.A. Use of sulfated fucans as anticoagulant and antithrombotic agents: Future perspectives. Curr. Pharm. Des. 2004, 10, 967–981.
22. Tollefsen, D.M.; Pestka, C.A.; Monafo, W.J. Activation of heparin cofactor II by dermatan sulfate. J. Biol. Chem. 1983, 258, 6713–6716.
23. Santos, G.R.; Tovar, A.M.; Capillé, N.V.; Pereira, M.S.; Pomin, V.H.; Mourão, P.A. Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs. Drug Discov. Today 2014, 19, 1801–1807.
24. Weitz, J.I. Low-molecular-weight heparins. N. Engl. J. Med. 1992, 337, 688–698.
25. Patnaik, M.M.; Moll, S. Inherited antithrombin deficiency: A review. Haemophilia 2008, 14, 1229–1239.
26. Fonseca, R.J.; Oliveira, S.N.; Melo, F.R.; Pereira, M.G.; Benevides, N.M.; Mourão, P.A. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities. Thromb. Haemost. 2008, 99, 539–545.
27. Sasisekharan, R.; Venkataraman, G. Heparin and heparan sulfate: Biosynthesis, structure and function. Curr. Opin. Chem. Biol. 2000, 4, 626–631.
28. Rabestein, D.L. Heparin and heparan sulfate: Structure and function. Nat. Prod. Rep. 2002, 19, 312–331.
29. Pomin, V.H.; Mulloy, B. Current structural biology of the heparin interactome. Curr. Opin. Struct. Biol. 2015, 34, 17–25.
30. Pomin, V.H.; Park, Y.; Huang, R.; Heiss, C.; Sharp, J.S.; Azadi, P.; Prestegard, J.H. Exploiting enzyme specificities in digestions of chondroitin sulfates A and C: Production of well-defined hexasaccharides. Glycobiology 2012, 22, 826–838.
31. Mizumoto, S.; Yamada, S.; Sugahara, K. Molecular interactions between chondroitin-dermatan sulfate and growth factors/receptors/matrix proteins. Curr. Opin. Struct. Biol. 2015, 34, 35–42.
32. Li, B.; Lu, F.; Wei, X.; Zhao, R. Fucoidan: Structure and bioactivity. Molecules 2008, 13, 1671–1695.
33. Fitton, J.H. Therapies from fucoidan; multifunctional marine polymers. Mar. Drugs 2011, 9, 1731–1760.
34. Wijesinghe, W.A.J.P.; Jeon, Y.-J. Biological activities and potential industrial applications of fucose rich sulfated polysaccharides and fucoidans isolated from brown seaweeds: A review. Carbohydr. Pol. 2012, 88, 13–20.
35. Fitton, J.H.; Stringer, D.N. Karpiniec, S.S. Therapies from fucoidan: An update. Mar. Drugs 2015, 13, 5920–5946.
36. Farias, E.H.; Pomin, V.H.; Valente, A.P.; Nader, H.B.; Rocha, H.A.; Mourão, P.A. A preponderantly 4-sulfated, 3-linked galactan from the green alga Codium isthmocladum. Glycobiology 2008, 18, 250–259.
37. Pomin, V.H. Structural and functional insights into sulfated galactans: A systematic review. Glycoconj. J. 2010, 27, 1–12.
38. Danielsson, A.; Björk, I. Properties of antithrombin-thrombin complex formed in the presence and in the absence of heparin. Biochem. J. 1983, 213, 345–353.
39. Liu, L.; Dewar, L.; Song, Y.; Kulczycky, M.; Blajchman, M.A.; Fenton 2nd, J.W.; Andrew, M.; Delorme, M.; Ginsberg, J.; Preissner, K.T.; et al. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb. Haemost. 1995, 73, 405–412.
40. Maaroufi, R.M.; Jozefowicz, M.; Tapon-Bretaudière, J.; Jozefonvicz, J.; Fischer, A.M. Mechanism of thrombin inhibition by heparin cofactor II in the presence of dermatan sulphates, native or oversulphated, and a heparin-like dextran derivative. Biomaterials 1997, 18, 359–366.
41. Tollefsen, D.M. Vascular dermatan sulfate and heparin cofactor II. Prog. Mol. Biol. Transl. Sci. 2010, 93, 351–372.
42. Pomin, V.H. Anticoagulant motifs of marine sulfated glycans. Glycoconj. J. 2014, 31, 341–344.
43. Pomin, V.H.; Mourão, P.A. Specific sulfation and glycosylation—a structural combination for the anticoagulation of marine carbohydrates. Front. Cell. Infect. Microbiol. 2014, 4, 33, doi: 10.3389/fcimb.2014.00033.
44. Zhao, L.; Wu, M.; Xiao, C.; Yang, L.; Zhou, L.; Gao, N.; Li, Z.; Chen, J.; Chen, J.; Liu, J.; Qian, H.; Zhao, J. Discovery of an intrinsic tenase complex inhibitor: Pure nonasaccharide from fucosylated glycosaminoglycan. Proc. Natl. Acad. Sci. USA 2015, 112, 8284–8289.
45. Otrock, Z.K.; Mahfouz, R.A.; Makarem, J.A.; Shamseddine, A.I. Understanding the biology of angiogenesis: Review of the most important molecular mechanisms. Blood Cells Mol. Dis. 2007, 39, 212–220.
46. Faham, S.; Hileman, R.E.; Fromm, J.R.; Linhardt, R.J.; Rees, D.C. Heparin structure and interactions with basic fibroblast growth factor. Science 1996, 271, 1116–1120.
47. Pellegrini, L.; Burke, D.F.; von Delft, F.; Mulloy, B.; Blundell, T.L. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000, 407, 1029–1034.
48. Schlessinger, J.; Plotnikov, A.N.; Ibrahimi, O.A.; Eliseenkova, A.V.; Yeh, B.K.; Yayon, A.; Linhardt, R.J.; Mohammadi, M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell. 2000, 6, 743–750.
49. Goodger, S.J.; Robinson, C.J.; Murphy, K.J.; Gasiunas, N.; Harmer, N.J.; Blundell, T.L.; Pye, D.A.; Gallagher, J.T. Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J. Biol. Chem. 2008, 283, 13001–13008.
50. Robinson, C.J.; Harmer, N.J.; Goodger, S.J.; Blundell, T.L.; Gallagher, J.T. Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes. J. Biol. Chem. 2005, 280, 42274–42282.
51. Guerrini, M.; Hricovíni, M.; Torri, G. Ineraction of heparins with fibroblast growth factors: conformational aspects. Curr. Pharm. Des. 2007, 13, 2045–2056.
52. Guglier, S.; Hricovíni, M.; Raman, R.; Polito, L.; Torri, G.; Casu, B.; Sasisekharan, R.; Guerrini, M. Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy. Biochemistry 2008, 47, 13862–13869.
53. Teran, M.; Nugent, M.A. Synergistic binding of vascular endothelial growth factor-A and its receptors to heparin selectively modulates complex affinity. J. Biol. Chem. 2015, 290, 16451–16462.
54. Yao, D.; Dai, C.; Peng, S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol. Cancer Res. 2011, 9, 1608–1620.
55. Khosravi Shahi, P.; Soria Lovelle, A.; Pérez Manga, G. Tumoral angiogenesis and breast cancer. Clin. Transl. Oncol. 2009, 11, 138–142.
56. Nishida, N.; Yano, H.; Nishida, T.; Kamura, T.; Kojiro, M. Angiogenesis in cancer. Vasc. Health Risk Manag. 2006, 2, 213–219.
57. Cumashi, A.; Ushakova, N.A.; Preobrazhenskaya, M.E.; D’Incecco, A.; Piccoli, A.; Totani, L.; Tinari, N.; Morozevich, G.E.; Berman, A.E.; Bilan, M.I.; et al. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology 2007, 17, 541–552.
58. Ustyuzhanina, N.E.; Bilan, M.I.; Ushakova, N.A.; Usov, A.I.; Kiselevskiy, M.V.; Nifantiev, N.E. Fucoidans: Pro- or antiangiogenic agents? Glycobiology 2014, 24, 1265–1274.
59. Kwak, J.Y. Fucoidan as a Marine anticancer agent in preclinical development. Mar. Drugs 2014, 12, 851–870.
60. Zemani, F.; Benisvy, D.; Galy-Fauroux, I.; Lokajczyk, A.; Colliec-Jouault, S.; Uzan, G.; Fischer, A.M.; Boisson-Vidal, C. Low-molecular-weight fucoidan enhances the proangiogenic phenotype of endothelial progenitor cells. Biochem. Pharmacol. 2005, 15, 1167–1175.
61. Dube, D.H.; Bertozzi, C.R. Glycans in cancer and inflammation—potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 2005, 4, 477–488.
62. Lowe, J.B. Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr. Opin. Cell Biol. 2003, 15, 531–538.
63. McEver, R.P. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj. J. 1997, 14, 585–591.
64. Pomin, V.H. Sulfated glycans in inflammation. Eur. J. Med. Chem. 2015, 92, 353–369.
65. Albuquerque, I.R.; Cordeiro, S.L.; Gomes, D.L.; Dreyfuss, J.L.; Filgueira, L.G.; Leite, E.L.; Nader, H.B.; Rocha, H.A. Evaluation of anti-nociceptive and anti-inflammatory activities of a heterofucan from Dictyota menstrualis. Mar. Drugs 2013, 11, 2722–2740.
66. De Sousa, A.A.; Benevides, N.M.; de Freitas Pires, A.; Fiúza, F.P.; Queiroz, M.G.; Morais, T.M.; Pereira, M.G.; Assreuy, A.M. A report of a galactan from marine alga Gelidium crinale with in vivo anti-inflammatory and antinociceptive effects. Fundam. Clin. Pharmacol. 2013, 27, 173–180.
67. Li, X.J.; Ye, Q.F. Fucoidan reduces inflammatory response in a rat model of hepatic ischemia-reperfusion injury. Can. J. Physiol. Pharmacol. 2015, 93, 999–1005.
68. Lean, Q.Y.; Eri, R.D.; Fitton, J.H.; Patel, R.P.; Gueven, N. Fucoidan extracts ameliorate acute colitis. PLoS ONE 2015, 10, e0128453.
69. Jinno, A.; Park, P.W. Role of glycosaminoglycans in infectious disease. Methods Mol. Biol. 2015, 1229, 567–585.
70. Sawitzky, D. Protein-glycosaminoglycan interactions: Infectiological aspects. Med. Microbiol. Immunol. 1996, 184, 155–161.
71. Baron, M.J.; Wong, S.L.; Nybakken, K.; Carey, V.J.; Madoff, L.C. Host glycosaminoglycan confers susceptibility to bacterial infection in Drosophila melanogaster. Infect. Immun. 2009, 77, 860–866.
72. Chang, Y. C.; Wang, Z.; Flax, L. A.; Xu, D.; Esko, J. D.; Nizet, V.; Baron, M. J. Glycosaminoglycan binding facilitates entry of a bacterial pathogen into central nervous systems. PLoS Pathog. 2011, 7, e1002082.
73. Sava, I.G.; Zhang, F.; Toma, I.; Theilacker, C.; Li, B.; Baumert, T.F.; Holst, O.; Linhardt, R.J.; Huebner, J. Novel interactions of glycosaminoglycans and bacterial glycolipids mediate binding of enterococci to human cells. J. Biol. Chem. 2009, 284, 18194–18201.
74. Wadström, T.; Ljungh, A. Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: key events in microbial pathogenicity. J. Med. Microbiol. 1999, 48, 223–233.
75. Leistner, C.M.; Gruen-Bernhard, S.; Glebe, D. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell. Microbiol. 2008, 10, 122–133.
76. Hallak, L.K.; Spillmann, D.; Collins, P.L.; Peeples, M.E. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J. Virol. 2000, 74, 10508–10513.
77. Bose, S.; Banerjee, A. K. Role of heparan sulfate in human parainfluenza virus type 3 infection. Virology 2002, 298, 73–83.
78. Vivès, R.R.; Imberty, A.; Sattentau, Q.J.; Lortat-Jacob, H. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J. Biol. Chem. 2005, 280, 21353–21357.
79. Patel, M.; Yanagishita, M.; Roderiquez, G.; Bou-Habib, D.C.; Oravecz, T.; Hascall, V.C.; Norcross, M.A. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retroviruses 1993, 9, 167–174.
80. Srinoulprasert, Y.; Kongtawelert, P.; Chaiyaroj, S.C. Chondroitin sulfate B and heparin mediate adhesion of Penicillium marneffei conidia to host extracellular matrices. Microb. Pathog. 2006, 40, 126–132.
81. Muller, H.M.; Reckmann, I.; Hollingdale, M.R.; Bujard, H.; Robson, K.J.; Crisanti, A. Thrombospondin-related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells, suggesting a role for this molecule in sporozoite invasion of hepatocytes. EMBO J. 1993, 12, 2881–2889.
82. Yokoyama, N.; Okamura, M.; Igarashi, I. Erythrocyte invasion by Babesia parasites: Current advances in the elucidation of the molecular interactions between the protozoan ligands and host receptors in the invasion stage. Vet. Parasitol. 2006, 138, 22–32.
83. Pomin, V.H. Antimicrobial sulfated glycans: Structure and function. Curr. Top. Med. Chem. 2015, doi: 10.2174/1568026615666150605104444.
84. Rosett, W.; Hodges, G.R. Antimicrobial Activity of Heparin. J. Clin. Microbiol. 1980, 11, 30–34.
85. Yamada, S.; Sugahara, K. Potential therapeutic application of chondroitin sulfate/dermatan sulfate. Curr. Drug Discov. Technol. 2008, 5, 289–301.
86. Schaeffer, D.J.; Krylov, V.S. Anti-HIV activity of extracts and compounds from algae and cyanobacteria. Ecotoxicol. Environ. Saf. 2000, 45, 208–227.
87. Wang, W.; Wang, S.X.; Guan, H.S. The antiviral activities and mechanisms of marine polysaccharides: An overview. Mar. Drugs 2012, 10, 2795–2816.
88. Pangestuti, R.; Kim, S.K. Biological activities of carrageenan. Adv. Food Nutr. Res. 2014, 72, 113–124.
89. Ahmed, A.B.; Adel, M.; Karimi, P.; Peidayesh, M. Pharmaceutical, cosmeceutical, and traditional applications of marine carbohydrates. Adv. Food Nutr. Res. 2014, 73, 197–220.
90. Irhimeh, M.R.; Fitton, J.H.; Lowenthal, R.M. Pilot clinical study to evaluate the anticoagulant activity of fucoidan. Blood Coagul. Fibrinolysis 2009, 20, 607–610.
91. Fonseca, R.J.; Oliveira, S.N.; Pomin, V.H.; Mecawi, A.S.; Araujo, I.G.; Mourão, P.A. Effects of oversulfated and fucosylated chondroitin sulfates on coagulation. Challenges for the study of anticoagulant polysaccharides. Thromb. Haemost. 2010, 103, 994–1004.